<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37672869</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2352-3964</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><PubDate><Year>2023</Year><Month>Oct</Month></PubDate></JournalIssue><Title>EBioMedicine</Title><ISOAbbreviation>EBioMedicine</ISOAbbreviation></Journal><ArticleTitle>Predictive models of long COVID.</ArticleTitle><Pagination><StartPage>104777</StartPage><MedlinePgn>104777</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">104777</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ebiom.2023.104777</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2352-3964(23)00343-2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The cause and symptoms of long COVID are poorly understood. It is challenging to predict whether a given COVID-19 patient will develop long COVID in the future.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We used electronic health record (EHR) data from the National COVID Cohort Collaborative to predict the incidence of long COVID. We trained two machine learning (ML) models - logistic regression (LR) and random forest (RF). Features used to train predictors included symptoms and drugs ordered during acute infection, measures of COVID-19 treatment, pre-COVID comorbidities, and demographic information. We assigned the 'long COVID' label to patients diagnosed with the U09.9 ICD10-CM code. The cohorts included patients with (a) EHRs reported from data partners using U09.9 ICD10-CM code and (b) at least one EHR in each feature category. We analysed three cohorts: all patients (n&#xa0;=&#xa0;2,190,579; diagnosed with long COVID&#xa0;=&#xa0;17,036), inpatients (149,319; 3,295), and outpatients (2,041,260; 13,741).</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">LR and RF models yielded median AUROC of 0.76 and 0.75, respectively. Ablation study revealed that drugs had the highest influence on the prediction task. The SHAP method identified age, gender, cough, fatigue, albuterol, obesity, diabetes, and chronic lung disease as explanatory features. Models trained on data from one N3C partner and tested on data from the other partners had average AUROC of 0.75.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">ML-based classification using EHR information from the acute infection period is effective in predicting long COVID. SHAP methods identified important features for prediction. Cross-site analysis demonstrated the generalizability of the proposed methodology.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">NCATS U24 TR002306, NCATS UL1 TR003015, Axle Informatics Subcontract: NCATS-P00438-B, NIH/NIDDK/OD, PSR2015-1720GVALE_01, G43C22001320007, and Director, Office of Science, Office of Basic Energy Sciences of the U.S. Department of Energy Contract No. DE-AC02-05CH11231.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Author(s). Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Antony</LastName><ForeName>Blessy</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Computer Science, Virginia Polytechnic Institute and State University (Virginia Tech), Blacksburg, VA, 24061, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blau</LastName><ForeName>Hannah</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>The Jackson Laboratory for Genomic Medicine, Farmington, CT, 06032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casiraghi</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>AnacletoLab, Computer Science Department, Dipartimento di Informatica, Universit&#xe0; degli Studi di Milano, Milan, 20133, Italy; Division of Environmental Genomics and Systems Biology, Lawrence Berkeley National Laboratory, Berkeley, CA, 94720, USA; ELLIS - European Laboratory for Learning and Intelligent Systems, Milan Unit, Milan, 20133, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loomba</LastName><ForeName>Johanna J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Integrated Translational Health Research Institute of Virginia, University of Virginia, Charlottesville, VA, 22904, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Callahan</LastName><ForeName>Tiffany J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laraway</LastName><ForeName>Bryan J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilkins</LastName><ForeName>Kenneth J</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Biostatistics Program, Office of the Director, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, 20814, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antonescu</LastName><ForeName>Corneliu C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Banner Health, University of Arizona, Phoenix, AZ, 85006, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valentini</LastName><ForeName>Giorgio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>AnacletoLab, Computer Science Department, Dipartimento di Informatica, Universit&#xe0; degli Studi di Milano, Milan, 20133, Italy; ELLIS - European Laboratory for Learning and Intelligent Systems, Milan Unit, Milan, 20133, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Andrew E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Institute for Clinical Research and Health Policy Studies, Tufts University School of Medicine, Boston, MA, 02111, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robinson</LastName><ForeName>Peter N</ForeName><Initials>PN</Initials><AffiliationInfo><Affiliation>The Jackson Laboratory for Genomic Medicine, Farmington, CT, 06032, USA; Institute for Systems Genomics, University of Connecticut, Farmington, CT, 06269, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reese</LastName><ForeName>Justin T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Division of Environmental Genomics and Systems Biology, Lawrence Berkeley National Laboratory, Berkeley, CA, 94720, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murali</LastName><ForeName>T M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Computer Science, Virginia Polytechnic Institute and State University (Virginia Tech), Blacksburg, VA, 24061, USA. Electronic address: murali@cs.vt.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>N3C consortium</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UM1 TR004404</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002649</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001433</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001422</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001860</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001427</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM104942</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001420</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001439</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002243</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001445</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003096</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UM1 TR004556</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM104938</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002537</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001412</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001872</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001878</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002529</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001863</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002494</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002736</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM115516</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002369</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002541</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM115371</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002001</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002538</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM115458</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001442</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002535</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001866</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003167</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001409</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001449</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001453</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002489</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM104940</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003107</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>INV-018455</GrantID><Acronym>GATES</Acronym><Agency>Bill &amp; Melinda Gates Foundation</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003015</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002733</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 TR002306</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002003</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001876</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001436</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002378</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002384</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002553</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002389</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001414</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM104941</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002014</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002550</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002319</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001855</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001425</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002373</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002240</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002556</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003017</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001998</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001873</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001881</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002645</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001450</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002366</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM115428</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002345</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002377</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM115677</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002544</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003098</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001430</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003142</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>EBioMedicine</MedlineTA><NlmUniqueID>101647039</NlmUniqueID><ISSNLinking>2352-3964</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="N">Machine Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009765" MajorTopicYN="N">Obesity</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Classification</Keyword><Keyword MajorTopicYN="N">Cross-site analysis</Keyword><Keyword MajorTopicYN="N">Explainability</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword></KeywordList><CoiStatement>Declaration of interests J Loomba received consulting fees from Axle Informatics as a subject matter expert for RadxUp Long COVID computational challenge (L3C). The other authors declare no competing interests.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Chute</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>7</Day><Hour>6</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>7</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>6</Day><Hour>18</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>9</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37672869</ArticleId><ArticleId IdType="pmc">PMC10494314</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2023.104777</ArticleId><ArticleId IdType="pii">S2352-3964(23)00343-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bennett T.D., Moffitt R.A., Hajagos J.G., et al. Clinical characterization and prediction of clinical severity of SARS-CoV-2 infection among US adults using data from the US national COVID cohort collaborative. JAMA Netw Open. 2021;4(7)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8278272</ArticleId><ArticleId IdType="pubmed">34255046</ArticleId></ArticleIdList></Reference><Reference><Citation>Reese J.T., Coleman B., Chan L., et al. NSAID use and clinical outcomes in COVID-19 patients: a 38-center retrospective cohort study. Virol J. 2022;19(1):84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9107579</ArticleId><ArticleId IdType="pubmed">35570298</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC. Centers for Disease Control and Prevention  Post-COVID conditions: overview for healthcare providers. 2020. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html [cited 2022 Aug 31]. Available from:</Citation></Reference><Reference><Citation>Tsampasian V., Elghazaly H., Chattopadhyay R., et al. Risk factors associated with post&#x2212;COVID-19 condition: a systematic review and meta-analysis. JAMA Intern Med. 2023;183(6):566&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10037203</ArticleId><ArticleId IdType="pubmed">36951832</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A., Nirantharakumar K., Hughes S., et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022;28:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Coronavirus disease (COVID-19): post COVID-19 condition. 2021. https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-post-covid-19-condition [cited 2022 Sep 6]. Available from:</Citation></Reference><Reference><Citation>Pfaff E.R., Girvin A.T., Bennett T.D., et al.  Identifying who has long COVID in the USA: a machine learning approach using N3C data. Lancet Digit Health. 2022;0(0) https://www.thelancet.com/journals/landig/article/PIIS2589-7500(22)00048-6/fulltext [cited 2022 Jun 1]. Available from:</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9110014</ArticleId><ArticleId IdType="pubmed">35589549</ArticleId></ArticleIdList></Reference><Reference><Citation>Deer R.R., Rock M.A., Vasilevsky N., et al. Characterizing long COVID: deep Phenotype of a complex condition. eBioMedicine. 2021;74</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8613500</ArticleId><ArticleId IdType="pubmed">34839263</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y., Yuan D., Chen D.G., et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185(5):881&#x2013;895.e20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal A.D., VanElzakker M.B. Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front Microbiol. 2021;12 https://www.readcube.com/articles/10.3389%2Ffmicb.2021.698169 [cited 2022 Mar 28] Available from:</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Rando H.M., Bennett T.D., Byrd J.B., et al.  Challenges in defining long COVID: striking differences across literature, electronic health records, and patient-reported information. Cold Spring Harbor Laboratory. 2021 https://www.scinapse.io [cited 2022 Mar 28]. Available from:</Citation></Reference><Reference><Citation>Pfaff E.R., Madlock-Brown C., Baratta J.M., et al. Coding long COVID: characterizing a new disease through an ICD-10 lens. BMC Med. 2023;21(1):58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9931566</ArticleId><ArticleId IdType="pubmed">36793086</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre C.H., Murray B., Varsavsky T., et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626&#x2013;631.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21:1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledford H. Long-COVID treatments: why the world is still waiting. Nature. 2022;608(7922):258&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">35945375</ArticleId></ArticleIdList></Reference><Reference><Citation>Gavriilaki E., Kokoris S. COVID-19 sequelae: can long-term effects be predicted? Lancet Infect Dis. 2022;0(0) https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00529-1/fulltext [cited 2022 Sep 12]. Available from:</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9411257</ArticleId><ArticleId IdType="pubmed">36030797</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan D., Pareek M. Toward a universal definition of post&#x2013;COVID-19 condition&#x2014;how do we proceed? JAMA Netw Open. 2023;6(4)</Citation><ArticleIdList><ArticleId IdType="pubmed">37017975</ArticleId></ArticleIdList></Reference><Reference><Citation>Raveendran A.V., Jayadevan R., Sashidharan S. Long COVID: an overview. Diabetes Metab Syndr Clin Res Rev. 2021;15(3):869&#x2013;875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9637465</ArticleId><ArticleId IdType="pubmed">36351871</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z., Xie Y., Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594(7862):259&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>McGrath L.J., Scott A.M., Surinach A., Chambers R., Benigno M., Malhotra D. Use of the postacute sequelae of COVID-19 diagnosis code in routine clinical practice in the US. JAMA Netw Open. 2022;5(10)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9539719</ArticleId><ArticleId IdType="pubmed">36201207</ArticleId></ArticleIdList></Reference><Reference><Citation>ICD10Data.com. 2022 ICD-10-CM Diagnosis Code U09.9: Post COVID-19 condition, unspecified. https://www.icd10data.com/ICD10CM/Codes/U00-U85/U00-U49/U09-/U09.9 [cited 2022 Mar 28]. Available from:</Citation></Reference><Reference><Citation>Haendel M.A., Chute C.G., Bennett T.D., et al. The national COVID cohort collaborative (N3C): rationale, design, infrastructure, and deployment. J&#xa0;Am Med Inform Assoc. 2021;28(3):427&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454687</ArticleId><ArticleId IdType="pubmed">32805036</ArticleId></ArticleIdList></Reference><Reference><Citation>Nick T.G., Campbell K.M. In: Topics in biostatistics. Ambrosius W.T., editor. Humana Press; Totowa, NJ: 2007. Logistic regression; pp. 273&#x2013;301. [cited 2022 Oct 11]</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-59745-530-5_14</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi Y. In: Ensemble machine learning: methods and applications. Zhang C., Ma Y., editors. Springer US; Boston, MA: 2012. Random forest for bioinformatics; pp. 307&#x2013;323. [cited 2022 Oct 11]</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4419-9326-7_11</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappelletti L., Petrini A., Gliozzo J., et al. Boosting tissue-specific prediction of active cis-regulatory regions through deep learning and Bayesian optimization techniques. BMC Bioinformatics. 2022;23(2):154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9743524</ArticleId><ArticleId IdType="pubmed">36510125</ArticleId></ArticleIdList></Reference><Reference><Citation>N3C Consortium . 2021. N3C privacy-preserving record linkage and linked data governance.https://zenodo.org/record/5165212 [cited 2022 Sep 14]. Available from:</Citation></Reference><Reference><Citation>N3C cohort exploration. https://covid.cd2h.org/dashboard/cohort [cited 2022 Mar 28]. Available from:</Citation></Reference><Reference><Citation>National Center for Advancing Translational Sciences (NCATS)  National center for advancing translational sciences. 2020. https://ncats.nih.gov/n3c/about/data-overview [cited 2022 Oct 11].</Citation></Reference><Reference><Citation>ICD10Data.com ICD-10-CM diagnosis code U07.1: COVID-19. 2022. https://www.icd10data.com/ICD10CM/Codes/U00-U85/U00-U49/U07-/U07.1 [cited 2022 Apr 12]. Available from:</Citation></Reference><Reference><Citation>Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A&#xa0;new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J&#xa0;Chronic Dis. 1987;40(5):373&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pubmed">3558716</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC. Centers for Disease Control and Prevention  COVID-19 and your health. 2020. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html [cited 2022 Mar 29]. Available from:</Citation><ArticleIdList><ArticleId IdType="pubmed">35324136</ArticleId></ArticleIdList></Reference><Reference><Citation>Callahan T.J., Stefanski A.L., Wyrwa J.M., et al. Ontologizing health systems data at scale: making translational discovery a reality. NPJ Digit Med. 2023;6(1):1&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10196319</ArticleId><ArticleId IdType="pubmed">37208468</ArticleId></ArticleIdList></Reference><Reference><Citation>Kursa M.B., Rudnicki W.R. Feature selection with the Boruta package. J&#xa0;Stat Softw. 2010;36:1&#x2013;13.</Citation></Reference><Reference><Citation>scikit-learn sklearn.model_selection.GridSearchCV. https://scikit-learn/stable/modules/generated/sklearn.model_selection.GridSearchCV.html [cited 2022 Aug 9]. Available from:</Citation></Reference><Reference><Citation>scikit-learn 3.1. Cross-validation: evaluating estimator performance. https://scikit-learn/stable/modules/cross_validation.html [cited 2022 Aug 9]. Available from:</Citation></Reference><Reference><Citation>Lundberg S.M., Lee S.I. Proceedings of the 31st international conference on neural information processing systems. Red Hook. Curran Associates Inc.; NY, USA: 2017. A&#xa0;unified approach to interpreting model predictions; pp. 4768&#x2013;4777. (NIPS&#x2019;17)</Citation></Reference><Reference><Citation>Lundberg S.M., Erion G., Chen H., et al. From local explanations to global understanding with explainable AI for trees. Nat Mach Intell. 2020;2(1):56&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7326367</ArticleId><ArticleId IdType="pubmed">32607472</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;ez C., Romero N., Conejero J.A., Garc&#xed;a-G&#xf3;mez J.M. Potential limitations in COVID-19 machine learning due to data source variability: a case study in the nCov2019 dataset. J&#xa0;Am Med Inform Assoc. 2021;28(2):360&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7797735</ArticleId><ArticleId IdType="pubmed">33027509</ArticleId></ArticleIdList></Reference><Reference><Citation>Reese J.T., Blau H., Casiraghi E., et al. Generalisable long COVID subtypes: findings from the NIH N3C and RECOVER programmes. eBioMedicine. 2023;87</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9769411</ArticleId><ArticleId IdType="pubmed">36563487</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran V.T., Porcher R., Pane I., Ravaud P. Course of post COVID-19 disease symptoms over time in the ComPaRe long COVID prospective e-cohort. Nat Commun. 2022;13(1):1812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8983754</ArticleId><ArticleId IdType="pubmed">35383197</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Keefe J.B., Newsom L.C., Taylor T.H. A&#xa0;survey of provider-reported use and perceived effectiveness of medications for symptom management in telemedicine and outpatient visits for mild COVID-19. Infect Dis Ther. 2021;10(2):839&#x2013;851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7982337</ArticleId><ArticleId IdType="pubmed">33748931</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinz&#xf3;n M.A., Ortiz S., Holgu&#xed;n H., et al. Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia. PLoS One. 2021;16(5)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8148307</ArticleId><ArticleId IdType="pubmed">34033648</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakur M., Datusalia A.K., Kumar A. Use of steroids in COVID-19 patients: a meta-analysis. Eur J Pharmacol. 2022;914</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8525014</ArticleId><ArticleId IdType="pubmed">34678244</ArticleId></ArticleIdList></Reference><Reference><Citation>Utrero-Rico A., Ruiz-Ruig&#xf3;mez M., Laguna-Goya R., et al. A&#xa0;short corticosteroid course reduces symptoms and immunological alterations underlying long-COVID. Biomedicines. 2021;9(11):1540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8614904</ArticleId><ArticleId IdType="pubmed">34829769</ArticleId></ArticleIdList></Reference><Reference><Citation>Beigel J.H., Tomashek K.M., Dodd L.E., et al. Remdesivir for the treatment of covid-19 &#x2014; final report. N&#xa0;Engl J Med. 2020;383(19):1813&#x2013;1826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7262788</ArticleId><ArticleId IdType="pubmed">32445440</ArticleId></ArticleIdList></Reference><Reference><Citation>Olender S.A., Perez K.K., Go A.S., et al. Remdesivir for severe coronavirus disease 2019 (COVID-19) versus a cohort receiving standard of care. Clin Infect Dis. 2021;73(11):e4166&#x2013;e4174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454434</ArticleId><ArticleId IdType="pubmed">32706859</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Zhang D., Du G., et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569&#x2013;1578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7190303</ArticleId><ArticleId IdType="pubmed">32423584</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang C., Wang Y., Lv H., Guan Z., Gu J. Caution against corticosteroid-based COVID-19 treatment. Lancet. 2020;395(10239):1759&#x2013;1760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7247780</ArticleId><ArticleId IdType="pubmed">32464115</ArticleId></ArticleIdList></Reference><Reference><Citation>Zha L., Li S., Pan L., et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19) Med J Aust. 2020;212(9):416&#x2013;420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7262211</ArticleId><ArticleId IdType="pubmed">32266987</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadalam P.K., Balaji T.M., Varadarajan S., et al. Assessing the therapeutic potential of agomelatine, ramelteon, and melatonin against SARS-CoV-2. Saudi J Biol Sci. 2022;29(5):3140&#x2013;3150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8788135</ArticleId><ArticleId IdType="pubmed">35095308</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R., Wang X., Ni L., et al. COVID-19: melatonin as a potential adjuvant treatment. Life Sci. 2020;250</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102583</ArticleId><ArticleId IdType="pubmed">32217117</ArticleId></ArticleIdList></Reference><Reference><Citation>Catalano A., Iacopetta D., Ceramella J., et al. Are nutraceuticals effective in COVID-19 and post-COVID prevention and treatment? Foods. 2022;11(18):2884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9498392</ArticleId><ArticleId IdType="pubmed">36141012</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrott B., Head R., Pringle K.G., Lumbers E.R., Martin J.H. &#x201c;LONG COVID&#x201d;&#x2014;a hypothesis for understanding the biological basis and pharmacological treatment strategy. Pharmacol Res Perspect. 2022;10(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8929332</ArticleId><ArticleId IdType="pubmed">35029046</ArticleId></ArticleIdList></Reference><Reference><Citation>Billett H.H., Reyes-Gil M., Szymanski J., et al. Anticoagulation in COVID-19: effect of enoxaparin, heparin, and apixaban on mortality. Thromb Haemost. 2020;120(12):1691&#x2013;1699.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7869055</ArticleId><ArticleId IdType="pubmed">33186991</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto M.D., Lambert N., Downs C.A., et al. Antihistamines for postacute sequelae of SARS-CoV-2 infection. J&#xa0;Nurse Pract. 2022;18(3):335&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8820139</ArticleId><ArticleId IdType="pubmed">35153633</ArticleId></ArticleIdList></Reference><Reference><Citation>Reznikov L.R., Norris M.H., Vashisht R., et al. Identification of antiviral antihistamines for COVID-19 repurposing. Biochem Biophys Res Commun. 2021;538:173&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7713548</ArticleId><ArticleId IdType="pubmed">33309272</ArticleId></ArticleIdList></Reference><Reference><Citation>Mashauri H.L. Covid-19 Histamine theory: why antihistamines should be incorporated as the basic component in Covid-19 management? Health Sci Rep. 2023;6(2):e1109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9903129</ArticleId><ArticleId IdType="pubmed">36778771</ArticleId></ArticleIdList></Reference><Reference><Citation>Mor&#xe1;n Blanco J.I., Alvarenga Bonilla J.A., Fremont-Smith P., Villar G&#xf3;mez de las Heras K. Antihistamines as an early treatment for Covid-19. Heliyon. 2023;9(5)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10129342</ArticleId><ArticleId IdType="pubmed">37128299</ArticleId></ArticleIdList></Reference><Reference><Citation>2022 ICD-10-CM Diagnosis Code B94.8: sequelae of other specified infectious and parasitic diseases. https://www.icd10data.com/ICD10CM/Codes/A00-B99/B90-B94/B94-/B94.8 [cited 2022 Aug 11]. Available from:</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>